Gentry Chris A, Giancola Stephanie E, Thind Sharanjeet, Kurdgelashvili George, Skrepnek Grant H, Williams Riley J
Pharmacy Service.
Medical Service, Oklahoma City VA Health Care System.
Open Forum Infect Dis. 2017 Nov 2;4(4):ofx235. doi: 10.1093/ofid/ofx235. eCollection 2017 Fall.
This study was conducted to compare clinical outcomes of oral vancomycin courses without taper versus oral vancomycin courses with taper for treatment of recurrent infection (CDI).
This investigation was a multicenter, retrospective, propensity score-matched analysis study using a Veterans Health Administration national clinical administrative database. Adult patients who were treated for recurrent CDI from any Veterans Affairs Medical Center between June 1, 2011 and October 31, 2016 were included if they were treated with oral vancomycin with or without a tapering regimen. The 2 groups were matched by next-nearest approach from a propensity score formula derived from independent variables associated with the selection of a taper regimen.
Propensity score matching resulted in 2 well-matched groups consisting of 226 episodes of patients treated with a vancomycin taper regimen and 678 episodes treated by vancomycin regimen without taper. No difference was found for the primary outcome of 180-day recurrence (59 of 226 [26.1%] for taper regimens versus 161 of 678 [23.8%], = .48). A secondary outcome of 90-day all-cause mortality met statistical significance, favoring a taper regimen (5.31% vs 9.29%, = .049); however, secondary outcomes of 90-day recurrence and 180-day all-cause mortality were not different.
Vancomycin taper regimens did not provide benefit over vancomycin regimens without taper in preventing additional CDI recurrence in patients with first or second recurrent episodes in this propensity score-matched analysis.
本研究旨在比较口服万古霉素疗程不减量与口服万古霉素疗程减量治疗复发性艰难梭菌感染(CDI)的临床结局。
本调查是一项多中心、回顾性、倾向评分匹配分析研究,使用退伍军人健康管理局的国家临床管理数据库。纳入2011年6月1日至2016年10月31日期间在任何退伍军人事务医疗中心接受复发性CDI治疗的成年患者,这些患者接受了含或不含减量方案的口服万古霉素治疗。通过倾向评分公式的次近邻法,根据与减量方案选择相关的自变量对两组进行匹配。
倾向评分匹配产生了两组匹配良好的患者,一组为226例接受万古霉素减量方案治疗的患者,另一组为678例接受无减量万古霉素方案治疗的患者。180天复发的主要结局未发现差异(减量方案组226例中有59例[26.1%],无减量方案组678例中有161例[23.8%],P = 0.48)。90天全因死亡率的次要结局具有统计学意义,支持减量方案(5.31%对9.29%,P = 0.049);然而,90天复发和180天全因死亡率的次要结局没有差异。
在这项倾向评分匹配分析中,对于首次或第二次复发的患者,万古霉素减量方案在预防额外的CDI复发方面并不优于无减量的万古霉素方案。